In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
The approval allows it to market its products in the country
_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Subscribe To Our Newsletter & Stay Updated
